SCHEMBL2293955

SCHEMBL2293955

O=C1CC(C(=O)O)(N(NC(=O)OCc2ccccc2)C(=O)OCc2ccccc2)C(=O)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
NAAA Q02083 1/20 0.38
TSHR P16473 2/20 0.38
CASP3 P42574 1/20 0.38
MGLL Q99685 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSK P43235 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1324347 0.88 DDB1 (0.42) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL13651747 0.79 DDB1 (0.39) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL2297578 0.73 DDB1 (0.49) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL28436910 0.71 SMN1; SMN2 (0.46) SMN1; SMN2LMNAALDH1A1GAATSHR
SCHEMBL12424729 0.69 DDB1 (0.47) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL12355229 0.69 DDB1 (0.47) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL1086370 0.69 ALDH1A1 (0.60) DDB1CRBNALDH1A1GAANAAA
SCHEMBL10611547 0.68 DDB1 (0.62) DDB1CRBNSMN1; SMN2LMNAALDH1A1
SCHEMBL11868898 0.68 SMN1; SMN2 (0.56) SMN1; SMN2LMNAALDH1A1GAACTSL
SCHEMBL2361135 0.67 DDB1 (0.77) DDB1CRBNSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190497-A1 Process for production of 2,5 dioxopyrrolidine 3 carboxylate REN, PKD1, KCNT1 DDB1 3570/4885CRBN 4418/4885SMN1; SMN2 2198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.